Stockscreener 앱 받기
12.59
3.30%
-0.43
시장 영업 전:
12.75
0.16
+1.27%
전일 마감가:
$13.02
열려 있는:
$12.8
하루 거래량:
1.46M
Relative Volume:
0.77
시가총액:
$919.95M
수익:
-
순이익/손실:
$-148.00M
주가수익비율:
-2.8421
EPS:
-4.4299
순현금흐름:
$-135.66M
1주 성능:
-10.20%
1개월 성능:
-3.30%
6개월 성능:
+179.16%
1년 성능:
+0.00%
1일 변동 폭
$12.28
$12.88
1주일 범위
$12.10
$15.15
52주 변동 폭
$3.76
$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
12.59 | 919.95M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | TD Cowen | Buy |
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Helus Pharma Inc 주식(HELP)의 최신 뉴스
Cybin (CYBN) Presented 12 Month HLP003 Efficacy Data At A Psychiatry Congress - simplywall.st
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention? - finance.yahoo.com
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - finance.yahoo.com
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Helus Pharma at TD Cowen summit: late-stage psychedelic bet takes shape - Investing.com Canada
Cybin Inc. at TD Cowen Novel Mechanisms in Neuropsychiatry Conference (Virtual) Transcript - GuruFocus
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
HELP News Today | Why did Cybin stock go up today? $HELP - MarketBeat
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change - Investing News Network
Helus Pharma Shareholders Approve Name Change and Governance Resolutions - TipRanks
Helus Pharma shareholders approve name change from Cybin Inc. By Investing.com - Investing.com Nigeria
Helus Pharma shareholders approve name change from Cybin Inc. - Investing.com
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - quiverquant.com
Helus Pharma (HELP.NE) Shareholders Approve Legal Name Change from Cybin Inc., Directors Elected at Annual Meeting - kalkine.ca
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - MarketBeat
Cybin Inc. Annual Shareholders Meeting Transcript - GuruFocus
Phase 3 Depression Data Could Define The Case For Cybin Stock - simplywall.st
Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast - Stock Titan
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Helus Pharma (HELP.NE) CEO to Join TD Cowen Neuropsychiatry Summit Fireside Chat on September 23 - kalkine.ca
Cybin highlights Phase 3 psychedelic depression drug | HELP SEC FilingForm 6-K - Stock Titan
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 - Investing News Network
Helus Pharma presents data on depression drug candidate HLP003 By Investing.com - Investing.com Canada
Helus Pharma (HELP) Showcases Key HLP003 Data at Psych Congress 2026 Amid High Valuation Metrics - GuruFocus
A potential depression treatment has 12-month efficacy results. Helus Pharma is testing it in a late-stage study. - Stock Titan
Barclays Sees Buying Opportunity in Helus Pharma (HELP) Amid Sha - GuruFocus
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 - finance.yahoo.com
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances - finance.yahoo.com
Helus Pharma Inc (HELP) Stock Price, Quote, News & History - benzinga.com
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results - TradingView
HELP Initiates Coverage On by Barclays -- Rating Set to Overweig - GuruFocus
Helus Pharma at Morgan Stanley conference: a broader depression bet By Investing.com - Investing.com Nigeria
Helus Pharma at Morgan Stanley conference: a broader depression bet - Investing.com
Cybin Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma at Cantor conference: phase III readout in focus - Investing.com
Canaccord Genuity maintains Buy on Helus Pharma, cuts target to $42 - scanx.trade
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - MarketBeat
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
symbol__ Stock Quote Price and Forecast - CNN
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
Helus Pharma (Nasdaq: HELP) CEO joins NYC investor fireside chat on Sept. 14 - stocktitan.net
Cybin (HELP) growth chief buys 90,000 shares in $1.04M trade - Stock Titan
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York - The Manila Times
Helus Pharma to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - quiverquant.com
HELP Watch: What's Behind Cybin Inc.'s Latest Move - kalkine.ca
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
Helus Pharma Inc (HELP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):